SSScott J. Dos Santos

Scott J. Dos Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Scott J. Dos Santos has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Not every gene is special: Modelling scale controls the false discovery rate when analysing high-throughput sequencing data

    by Scott J. Dos Santos, Andreea C. Murariu, Justin D. Silverman, Gregory B. Gloor

    Differential expression/abundance analyses are commonplace in studies employing high-throughput sequencing (HTS); however different tools often fail to return comparable results when applied to the same dataset. Most tools employ normalisations to attempt to correct for technical variation in the count data. Previously, we demonstrated that these normalisations are often inappropriate due to incorrect assumptions regarding the overall scale (i.e., size) of the biological system in question. In this study, we used a combination of binomial thinning and permutation of sample groupings to produce 100 analysis iterations of 11 RNA-seq and other HTS datasets in which ~ 5% of all features are expected to be significantly different between groups. This enabled calculation of the false discovery rate (FDR) and sensitivity across the iterations. Our simulations showed that scale misspecification results in poor control of the FDR by several commonly used tools and that, counterintuitively, FDRs increased as the modelled difference between groups increased. Implementing a scale model in ALDEx2 or ALDEx3 ameliorated unacceptably high FDRs; however, there was an inherent trade-off between satisfactory FDR control and high sensitivity- no tool offered both. We established that increasing scale uncertainty also increased the minimum difference between groups required for a feature to be reported as differentially expressed. This phenomenon was consistently observed in disparate types of HTS data and was remarkably consistent. Critically, we leveraged a ‘real-world’, non-permuted analysis of an RNA-seq dataset to demonstrate that the latter effect is not a result of our thinning/permutation approach. Overall, our work highlights the potentially unwitting choice between sensitivity and FDR control that all researchers are making when analysing sequencing data and provides guidance on choosing an appropriate amount of scale uncertainty for the analysis of HTS data.


  • Open Access

    Incorporating Scale Uncertainty into Differential Expression Analyses Using ALDEx2

    by Scott J. Dos Santos, Gregory B. Gloor

    Differential abundance or expression analyses are routinely performed on metagenomic, metatranscriptomic, and amplicon sequencing data. In such datasets, analysts usually have no information regarding the true scale (i.e., size) of the microbial community or sample under study, with inter‐sample differences in sequencing depth instead being driven by technical variation rather than biological factors. Recent work has demonstrated that normalizations used in all analysis tools make incorrect assumptions about the biological scale of the system in question, leading to unacceptably high false‐discovery rates in the output. To mitigate this, analysts can acknowledge and account for the uncertainty of the overall system scale during normalization by building scale models of the data—a feature that has been integrated into the ALDEx2 R package. Here, we provide reproducible examples that demonstrate how to incorporate scale models into differential expression analyses of RNA‐seq data using bulk transcriptome and metatranscriptomic datasets, as well as the consequences of not doing so. We also show how to use the output of ALDEx2 to create high‐level exploratory visualizations of their data through principal component analysis. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Using a simple scale model for differential expression analysis to avoid dual‐cutoff P value/significance thresholds Basic Protocol 2 : Implementing a full informed scale model to correct scale‐related data asymmetry in differential expression analyses Basic Protocol 3 : Visualizing ALDEx2 outputs using a compositional approach: Principal component analysis


  • Open Access

    Not every gene is special: one simple rule to control the false discovery rate when analysing high-throughput sequencing data

    by Scott J. Dos Santos, Andreea C. Murariu, Justin D. Silverman, Gregory B. Gloor

    1 Differential expression and differential abundance analyses are commonplace in studies employing high-throughput sequencing approaches; however different tools often fail to return comparable results when applied to the same dataset. Most tools employ various normalisations to attempt to correct for technical variation in the count data. Previously, we demonstrated that these normalisations are often inappropriate due to incorrect assumptions regarding the overall scale (i.e. size) of the biological system in question. In this study, we conducted 100 permutation analyses of 10 RNA-seq datasets to show that scale misspecification results in poor control of the false discovery rate by several commonly-used analysis tools. Moreover, we demonstrate that this can be ameliorated by using a scale model in ALDEx2 or ALDEx3 to account for uncertainty around the size of the system scale. We show that there is an inherent trade-off between satisfactory control of false-discovery rates and sensitivity and that no tool offers both. We also quantify how increasing scale uncertainty affects the difference between groups required for a feature to be reported as differentially expressed. Finally, we provide universal guidance on choosing an appropriate amount of scale uncertainty for any type of analysis. Overall, our work highlights the strengths and pitfalls of commonly used tools for differential expression analyses and highlights the choice between sensitivity and false-discovery rate control that all researchers are making when analysing sequencing data.


  • Open Access

    Vaginal metatranscriptome meta-analysis reveals functional BV subgroups and novel colonisation strategies

    by Scott J. Dos Santos, Clara Copeland, Jean M. Macklaim, Gregor Reid, Gregory B. Gloor

    The application of ‘-omics’ technologies to study bacterial vaginosis (BV) has uncovered vast differences in composition and scale between the vaginal microbiomes of healthy and BV patients. Compared to amplicon sequencing and shotgun metagenomic approaches focusing on a single or few species, investigating the transcriptome of the vaginal microbiome at a system-wide level can provide insight into the functions which are actively expressed and differential between states of health and disease. We conducted a meta-analysis of vaginal metatran-scriptomes from three studies, split into exploratory (n = 44) and validation (n = 297) datasets, accounting for the compositional nature of sequencing data and differences in scale between healthy and BV microbiomes. Conducting differential abundance analyses on the exploratory dataset, we identified a multitude of strategies employed by microbes associated with states of health and BV to evade host cationic antimicrobial peptides (CAMPs); putative mechanisms used by BV-associated species to resist and counteract the low vaginal pH; and potential approaches to disrupt vaginal epithelial integrity so as to establish sites for adherence and biofilm formation. Moreover, we identified several distinct functional subgroups within the BV population, distinguished by genes involved in motility, chemotaxis, biofilm formation and co-factor biosynthesis. After defining molecular states of health and BV in the validation dataset using KEGG orthology terms rather than community state types, differential abundance analysis confirmed earlier observations regarding CAMP resistance and compromising epithelial barrier integrity in healthy and BV microbiomes, and also supported the existence of motile vs. non-motile subgroups in the BV population. Our findings highlight a need to focus on functional rather than taxonomic differences when considering the role of microbiomes in disease and identify pathways for further research as potential BV treatment targets.


  • Open Access

    Birth Mode Does Not Determine the Presence of Shared Bacterial Strains between the Maternal Vaginal Microbiome and the Infant Stool Microbiome

    by Scott J. Dos Santos, Ishika Shukla, Janet E. Hill, Deborah M. Money, The Maternal Microbiome Legacy Project Team, K.S. Joseph, Julie E. van Schalkwyk, Arianne Y.K. Albert, Chelsea N. Elwood, Soren Gantt, et al.

    The importance of the gut microbiome in human health and disease is widely recognized, and there has been a growing appreciation that alterations in gut microbiome composition during a “critical window” of development may impact health in later life. Attempts to correct gut microbiome dysbiosis related to birth mode are underpinned by the assumption that the lack of exposure to maternal vaginal microbes during caesarean delivery is responsible for dysbiosis.


  • Open Access

    Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV

    by Elisabeth McClymont, Arianne Y Albert, Christine Wang, Scott J Dos Santos, François Coutlée, Marette Lee, Sharon Walmsley, Nancy Lipsky, Mona Loutfy, Sylvie Trottier, et al.

    Background: Women living with HIV (WLWH) experience higher rates of human papillomavirus (HPV) infection and cervical cancer than women without HIV. Changes in the vaginal microbiome have been implicated in HPV-related disease processes such as persistence of high-risk HPV infection but this has not been well defined in a population living with HIV. Methods: Four hundred and 20 girls and WLWH, age ≥9, across 14 clinical sites in Canada were enrolled to receive three doses of quadrivalent HPV vaccine for assessment of vaccine immunogenicity. Blood, cervical cytology, and cervico-vaginal swabs were collected. Cervico-vaginal samples were tested for HPV DNA and underwent microbiota sequencing. Results: Principal component analysis (PCA) and hierarchical clustering generated community state types (CSTs). Relationships between taxa and CSTs with HPV infection were examined using mixed-effects logistic regressions, Poisson regressions, or generalized linear mixed-effects models, as appropriate. Three hundred and fifty-six cervico-vaginal microbiota samples from 172 women were sequenced. Human papillomavirus DNA was detected in 211 (59%) samples; 110 (31%) contained oncogenic HPV. Sixty-five samples (18%) were taken concurrently with incident oncogenic HPV infection and 56 (16%) were collected from women with concurrent persistent oncogenic HPV infection. Conclusions: No significant associations between taxa, CST, or microbial diversity and HPV-related outcomes were found. However, we observed weak associations between a dysbiotic microbiome and specific species, including Gardnerella, Porphyromonas, and Prevotella species, with incident HPV infection.


  • Open Access

    Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β, are linked to fibrin formation in Buruli ulcer lesions

    by Louise Tzung-Harn Hsieh, Scott J. Dos Santos, Belinda S. Hall, Joy Ogbechi, Aloysius D. Loglo, Francisco Javier Salguero, Marie-Thérèse Ruf, Gerd Pluschke, Rachel E. Simmonds

    Buruli ulcer (BU) is a neglected tropical disease caused by subcutaneous infection withMycobacterium ulceransand its exotoxin mycolactone. BU displays coagulative necrosis and widespread fibrin deposition in affected skin tissues. Despite this, the role of the vasculature in BU pathogenesis remains almost completely unexplored. We hypothesise that fibrin-driven ischemia can be an ‘indirect’ route to mycolactone-dependent tissue necrosis by a mechanism involving vascular dysfunction. Here, we tracked >900 vessels within contiguous tissue sections from eight BU patient biopsies. Our aim was to evaluate their vascular and coagulation biomarker phenotype and explore potential links to fibrin deposition. We also integrated this with our understanding of mycolactone’s mechanism of action at Sec61 and its impact on proteins involved in maintaining normal vascular function. Our findings showed that endothelial cell dysfunction is common in skin tissue adjacent to necrotic regions. There was little evidence of primary haemostasis, perhaps due to mycolactone-dependent depletion of endothelial von Willebrand factor. Instead, fibrin staining appeared to be linked to the extrinsic pathway activator, tissue factor (TF). There was significantly greater than expected fibrin staining around vessels that had TF staining within the stroma, and this correlated with the distance it extended from the vessel basement membrane. TF-induced fibrin deposition in these locations would require plasma proteins outside of vessels, therefore we investigated whether mycolactone could increase vascular permeabilityin vitro. This was indeed the case, and leakage was further exacerbated by IL-1β. Mycolactone caused the loss of endothelial adherens and tight junctions by the depletion of VE-cadherin, TIE-1, TIE-2 and JAM-C; all Sec61-dependent proteins. Taken together, our findings suggest that both vascular and lymphatic vessels in BU lesions become “leaky” during infection, due to the unique action of mycolactone, allowing TF-containing structures and plasma proteins into skin tissue, ultimately leading to local coagulopathy and tissue ischemia.


  • Open Access

    Early Neonatal Meconium Does Not Have a Demonstrable Microbiota Determined through Use of Robust Negative Controls with cpn 60-Based Microbiome Profiling

    by Scott J. Dos Santos, Zahra Pakzad, Chelsea N. Elwood, Arianne Y. K. Albert, Soren Gantt, Amee R. Manges, Tim J. Dumonceaux, Evelyn J. Maan, Janet E. Hill, Deborah M. Money, et al.

    Much like the recent placental microbiome controversy, studies of neonatal meconium reporting bacterial communities within the fetal and neonatal gut imply that microbial colonization begins prior to birth. However, recent work has shown that placental microbiomes almost exclusively represent contamination from lab reagents and the environment.


  • Open Access

    Inhibition of the SEC61 translocon by mycolactone induces a protective autophagic response controlled by EIF2S1-dependent translation that does not require ULK1 activity

    by Belinda S Hall, Scott J Dos Santos, Louise Tzung-Harn Hsieh, Maria Manifava, Marie-Thérèse Ruf, Gerd Pluschke, Nicholas Ktistakis, Rachel E Simmonds

    The Mycobacterium ulcerans exotoxin, mycolactone, is responsible for the immunosuppression and tissue necrosis that characterizes Buruli ulcer. Mycolactone inhibits SEC61-dependent co-translational translocation of proteins into the endoplasmic reticulum and the resultant cytosolic translation triggers degradation of mislocalized proteins by the ubiquitin-proteasome system. Inhibition of SEC61 by mycolactone also activates multiple EIF2S1/eIF2α kinases in the integrated stress response (ISR). Here we show mycolactone increased canonical markers of selective macroautophagy/autophagy LC3B-II, ubiquitin and SQSTM1/p62 in diverse disease-relevant primary cells and cell lines. Increased formation of puncta positive for the early autophagy markers WIPI2, RB1CC1/FIP200 and ATG16L1 indicates increased initiation of autophagy. The mycolactone response was SEC61A1-dependent and involved a pathway that required RB1CC1 but not ULK. Deletion of Sqstm1 reduced cell survival in the presence of mycolactone, suggesting this response protects against the increased cytosolic protein burden caused by the toxin. However, reconstitution of baseline SQSTM1 expression in cells lacking all autophagy receptor proteins could not rescue viability. Translational regulation by EIF2S1 in the ISR plays a key role in the autophagic response to mycolactone. Mycolactone-dependent induction of SQSTM1 was reduced in eif2ak3−/-/perk−/- cells while the p-EIF2S1 antagonist ISRIB reversed the upregulation of SQSTM1 and reduced RB1CC1, WIPI2 and LC3B puncta formation. Increased SQSTM1 staining could be seen in Buruli ulcer patient skin biopsy samples, reinforcing genetic data that suggests autophagy is relevant to disease pathology. Since selective autophagy and the ISR are both implicated in neurodegeneration, cancer and inflammation, the pathway uncovered here may have a broad relevance to human disease. Abbreviations: ATF4: activating transcription factor 4; ATG: autophagy related; BAF: bafilomycin A1; ATG16L1: autophagy related 16 like 1; BU: Buruli ulcer; CQ: chloroquine; EIF2AK3: eukaryotic translation initiation factor 2 alpha kinase 3; CALCOCO2: calcium binding and coiled-coil domain 2; DMSO: dimethyl sulfoxide; EIF2S1: eukaryotic translation initiation factor 2 subunit alpha; ER: endoplasmic reticulum; GFP: green fluorescent protein; HDMEC: human dermal microvascular endothelial cells; HFFF: human fetal foreskin fibroblasts; ISR: integrated stress response; ISRIB: integrated stress response inhibitor; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MEF: mouse embryonic fibroblast; Myco: mycolactone; NBR1: NBR1 autophagy cargo receptor; NFE2L2: nuclear factor, erythroid 2 like 2; OPTN: optineurin; PFA: paraformaldehyde; PtdIns3P: phosphatidylinositol-3-phosphate; RB1CC1: RB1-inducible coiled coil 1; SQSTM1: sequestosome 1; TAX1BP1: Tax1 binding protein 1; ULK: unc-51 like autophagy activating kinase; UPS: ubiquitin-proteasome system; WIPI: WD repeat domain, phosphoinositide interacting; WT: wild type.


  • Open Access

    Evaluation of variant calling for cpn60 barcode sequence-based microbiome profiling

    by Sarah J. Vancuren, Scott J. Dos Santos, Janet E. Hill, the Maternal Microbiome Legacy Project Team

    Amplification and sequencing of conserved genetic barcodes such as the cpn60 gene is a common approach to determining the taxonomic composition of microbiomes. Exact sequence variant calling has been proposed as an alternative to previously established methods for aggregation of sequence reads into operational taxonomic units (OTU). We investigated the utility of variant calling for cpn60 barcode sequences and determined the minimum sequence length required to provide species-level resolution. Sequence data from the 5´ region of the cpn60 barcode amplified from the human vaginal microbiome (n = 45), and a mock community were used to compare variant calling to de novo assembly of reads, and mapping to a reference sequence database in terms of number of OTU formed, and overall community composition. Variant calling resulted in microbiome profiles that were consistent in apparent composition to those generated with the other methods but with significant logistical advantages. Variant calling is rapid, achieves high resolution of taxa, and does not require reference sequence data. Our results further demonstrate that 150 bp from the 5´ end of the cpn60 barcode sequence is sufficient to provide species-level resolution of microbiota.